DSIJ Mindshare

Double Dhamaka! 1:1 Bonus Share & 5:1 Stock Split: Multibagger pharma stock jumps 14.6 per cent; Promoters bought 13,02,000 shares!

From Rs 38.05 to Rs 198.80 per share, the stock gave multibagger returns of over 400 per cent in 3 years.

Kiran Shroff 2 936 Article rating: 4.3

In July 2024, the promoters of the company bought 13,02,000 shares and increased their stake to 31.61 per cent compared to 26.32 per cent in June 2024.

Multibagger pharma stock under Rs 65 is in the green as the company launches its new product lines, PureCoat and UltraMod; Details inside!

From Rs 35.03 per share (52-week low) to Rs 62.49 per share, the stock is up by 78.4 per cent and gave multibagger returns of 115 per cent in 2 years.

Kiran Shroff 0 2050 Article rating: 3.7

From Rs 35.03 per share (52-week low) to Rs 62.49 per share, the stock is up by 78.4 per cent and gave multibagger returns of 115 per cent in 2 years.

Multibagger penny stock under Rs 60 with 200 per cent returns: Heavy buying witnessed in this pharma stock; PAT jumps over 240 per cent!

Shares of the company gained more than 10 per cent in the last six months.

Praveenkumar Yadav 0 5748 Article rating: 4.0

Shares of the company gained more than 10 per cent in the last six months.

Record high FIIs stake in this multibagger pharma stock: Exploring the key tailwinds!

The company saw strong volume growth across key markets, particularly the US, indicating rising demand for their products.

Aniket Gogate 0 7918 Article rating: 4.0

Institutional investor interest in the stock has risen significantly, with Foreign Institutional Investor (FII) holdings increasing to 15.55 per cent in the quarter ending December 2023 from 4.23 per cent in December 2022.

Amansa Holding buys 11,40,301 shares of small-cap multibagger pharma stock; company reduces debt and presents special situation opportunity!

Moreover, the company's announcement regarding the creation of OneSource in September 2023 marks a pivotal value enhancement opportunity for Strides shareholders

Karan Dsij 0 15893 Article rating: 3.8

Of significant note is the remarkable reduction in the company's debt-to-EBITDA ratio, which has undergone a substantial decline from 5.7x in FY'22 to 2.8x on an annualized quarterly basis, signaling a notable financial transformation. Despite surpassing guidance in debt reduction, the company continues to generate free cash flow

RSS
12
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR